Sildenafil Citrate Tablet, Film Coated
Product Images NDC 70518-1641

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 70518-1641). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Sildenafil 50 mg tablet, quantity of 30 units. The label includes the NDC number 70518-1641-00, source NDC 13668-0187-30, and manufacturer listed as Torrent, Bharuch, India 392130. It indicates the product is prescription only (RX ONLY) and provides storage instructions along with a note to see the package insert for directions.*

FDA Label Image

Chemical Structure

Chemical structure diagram showing the molecular formula of a compound with multiple functional groups, including methoxy, sulfonyl, amide, and carboxylic acid groups. The structure also incorporates a piperazine ring and a purine-like bicyclic nitrogen-containing core.*

FDA Label Image

Figure 1

A line graph comparing systolic blood pressure (mmHg) changes over 24 hours post dose for Sildenafil 100mg and a placebo. The x-axis shows time in hours, including a pre-dose baseline, and the y-axis shows changes in systolic blood pressure. The graph includes two lines with markers representing the two treatments.*

FDA Label Image

Figure 2

A line graph showing the change in systolic blood pressure (SBP) in mmHg over 8 hours postdose. Two lines represent treatments: 'Doxazosin + Placebo' in grey and 'Doxazosin + Sildenafil 25 mg' in black. The graph indicates a decrease in SBP with both treatments, with the combination including Sildenafil showing a larger decrease during the initial hours.*

FDA Label Image

Figure 3

A line graph showing change in systolic blood pressure (SBP) in mmHg over time (0 to 8 hours postdose). Two lines represent comparison between Doxazosin + Placebo and Doxazosin + Sildenafil 50 mg, illustrating the variations in SBP reduction over the time period.*

FDA Label Image

Figure 4

A line graph depicting changes in mmHg over time after dosing, measured in hours from 0 to 8. Two lines represent different treatments: one for Doxazosin plus Sildenafil 100 mg and another for Doxazosin plus Placebo. Both lines start near zero mmHg and show a drop shortly after dosing, with the Doxazosin plus Sildenafil 100 mg line reaching a lower minimum before gradually rising again toward the end of the 8-hour period.*

FDA Label Image

Figure 5

A line graph depicting plasma concentrations (ng/ml) over time post dose (hours) for a commercial tablet treatment. The graph shows plasma levels rising sharply to a peak near 1 hour after dosing, then gradually declining over 24 hours with a slight rise around 24 hours.*

FDA Label Image

Figure 6 1

A bar chart showing the percentage of patients at the study endpoint across various baseline scores from 0 to 5. Each baseline score category has multiple bars representing different subgroups labeled 0 through 5. The vertical axis represents the percentage of patients, ranging from 0 to 80%. The chart illustrates changes in patient distribution at endpoint compared to baseline scores.*

FDA Label Image

Figure 6 2

A bar graph showing the percentage of patients at endpoint by baseline score categories from 0 to 5. Each baseline score has multiple bars representing different subgroups or conditions labeled 0 through 5, with varying percentage values on the y-axis up to 80%.*

FDA Label Image

Figure 7

A vertical bar chart displaying the percentage of patients reporting improvement. The x-axis lists four groups: Placebo (n=463), sildenafil citrate 25 mg (n=214), sildenafil citrate 50 mg (n=391), and sildenafil citrate 100 mg (n=380). The y-axis shows percentages from 0 to 100%. The placebo group reports 24%, sildenafil citrate 25 mg reports 63%, 50 mg reports 74%, and 100 mg reports 82% improvement.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.